Houlihan Lokey Advises Random42

Houlihan Lokey is pleased to announce that Random42, a best-in-class medical animation studio, has been successfully sold by Graphite Capital to The Lockwood Group, a portfolio company of a private equity fund managed by Ares Management. The transaction closed on June 1, 2022.

Founded in 1992, Random42 is a leading scientific communication studio specializing in medical animation and education, virtual reality, augmented and mixed reality, interactive and visually engaging solutions for global pharmaceutical and biotechnology companies. Random42 is the largest and most experienced company within the industry and has won over 260 awards for high-quality medical animation and scientific storytelling – a clear industry leader. Their clients range from the pharmaceutical giants, including all of the Top 25 pharma companies, down to small innovative biotechs (and everyone in between).

Founded in 2007 and headquartered in Stamford, Connecticut, Lockwood communicates clinical and therapeutic advances to every type of medical expert, healthcare practitioner, and decision maker. For the ultimate benefit of patients, Lockwood helps clients advance their objectives in a world of new regulations, business models, payment approaches, technologies, roles, and work practices. Lockwood teams are organized around the specific needs of each client. With extensive experience in oncology, rare diseases, and all major therapeutic areas, along with highly specialized knowledge in biologics, devices, and diagnostics, Lockwood can quickly deploy the right scientific, business, and communications experts to address the challenges at hand.

Houlihan Lokey served as the exclusive financial advisor to Random42 and Graphite Capital. This deal highlights Houlihan Lokey’s leading experience in the pharma services space and represents the firm’s 15th transaction in this sector since 2019.